- From: Eric Neumann <eneumann@teranode.com>
- Date: Fri, 28 Jul 2006 15:49:41 -0400
- To: "public-semweb-lifesci hcls" <public-semweb-lifesci@w3.org>
- Message-ID: <EF4BAB37-E76A-4C6F-B717-D37E3EF052E7@teranode.com>
ANNOUNCEMENT: A New Task force has been created to discuss how best to use semantic web standards to "R&D Informatics applied as part of Drug Safety and Efficacy". Specifically, this task force will focus on the following areas for scenarios and activities: Identify/address challenges and needs regarding Biomarkers and Pharmacogenomics in coordination with FDA guidelines Semantic applications around Drug Safety: Signals and Notification Possible applications of Semantic Web in Clinical Trial planning, management, analysis, and reporting (e.g., EDC and EHR Single-Source, data security, integrity) Facilitating electronic submissions as per the Common Technical Document (eCTD) specifications, http://www.fda.gov/cder/guidance/ 7087rev.htm The use of information to improve the development of Efficacious and Safe Drugs rests on the proper and timely utilization of diverse information sets, and the adoption and compliance to well-defined policies. As information becomes more diverse and policies more central to the industry, the development of information systems that are better suited to handle multiple information types (data and ontologies) while complying to defined policies (rules and actions) will become essential. Semantic Web technology standards offer potential solutions for: Aggregating Study Datasets, around Biomarkers (and following eCTD guidelines) Enhancing management of non-clinical and clinical controlled vocabularies that will be certainly expanding and evolving (adaptability) Providing fast access to current safety information though semantic- enabled channels (Pharmacovigilance) Applying Rules, Integrity, and Security in support of policy compliance and management (HIPAA, CFR21Part11 and Sarbanes-Oxley) This activity is open to mailing list participants and W3C members who are interested in this area. More information can be found at: http://esw.w3.org/topic/HCLSIG/Drug_Safety_and_Efficacy cheers, Eric Eric Neumann, PhD co-chair, W3C Healthcare and Life Sciences, and Senior Director Product Strategy Teranode Corporation 83 South King Street, Suite 800 Seattle, WA 98104 +1 (781)856-9132 www.teranode.com
Received on Friday, 28 July 2006 19:54:56 UTC